Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BioElectronics Corp. (OTC: BIEL).

Full DD Report for BIEL

You must become a subscriber to view this report.


Recent News from (OTC: BIEL)

BioElectronics President's Response to Stock Price Decline
Frederick, Maryland, Dec. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Dear Fellow Shareholders, While we were all disappointed by the dramatic drop in the stock price, it hasn’t had an impact on the Company’s operations. What is still needed is a cost-effective effic...
Source: GlobeNewswire
Date: December, 04 2018 08:30
BioElectronics Announces FDA Market Clearance Update
FREDERICK, MD, Nov. 27, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC Pink: BIEL), the maker of non-invasive electroceutical devices, announced that the U.S. Food & Drug Administration (FDA) declined the company’s 510(k) submission for ActiPatch ...
Source: GlobeNewswire
Date: November, 27 2018 09:31
BioElectronics Signs a Five Country Additional Distribution Agreement with Mundipharma Pty Limited, South East Asia
FREDERICK, MD, Nov. 15, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL),  www.bielcorp.com  is pleased to announce that Mundipharma Pty Limited, has added the ActiPatch® Musculoskeletal Pain Therapy medical device to its pain managemen...
Source: GlobeNewswire
Date: November, 15 2018 08:30
BioElectronics Discusses Advancing the Electroceuticals Market
PHOENIX, AZ/ ACCESSWIRE / November 13th, 2018 / BioElectronics Corporation (OTC PINK: BIEL), is a maker of advanced medical devices. Nalepka, VP of Sales and Marketing, talked with Stock Day's Everett Jolly about BioElectronics. Jolly began the interview by asking Nalepka to give an upda...
Source: ACCESSWIRE
Date: November, 13 2018 08:30
BioElectronics Announces Publication of Electroceuticals Article on Chronic Pain
FREDERICK, MD, Oct. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC Pink: BIEL), the maker of non-invasive electroceutical devices, announced the publication of an article in the October 2018 edition of the European Biopharmaceutical Review. Titled “Effe...
Source: GlobeNewswire
Date: October, 04 2018 08:30
BioElectronics' President Discusses ActiPatch's® Opioid Application
PHOENIX, Sept. 11, 2018 (GLOBE NEWSWIRE) -- President of BioElectronics Corporation (OTC Pink:BIEL) (“the Company”) goes back onto the “Stock Day” podcast. BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of the unique product...
Source: GlobeNewswire
Date: September, 11 2018 07:13
BioElectronics Applies for FDA's Opioid Alternative Innovation Challenge Program
FREDERICK, MD, Aug. 13, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com, is pleased to announce that it has submitted an application to the U.S. Food and Drug Administration’s 2018 Opioid Innovation Challenge. This challenge was designed by the ...
Source: GlobeNewswire
Date: August, 13 2018 07:30
BioElectronics ActiPatch Musculoskeletal Therapy Added to Mundipharma Australia's Pain Portfolio
FREDERICK, MD, July 23, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that Mundipharma Pty Limited (Mundipharma), https://www.mundipharma.com.au/ has added ActiPatch® to its pain management portfolio, by acquiring the ...
Source: GlobeNewswire
Date: July, 23 2018 08:30
BioElectronics Files FDA Application for Treatment of Musculoskeletal Pain
FREDERICK, MD, July 12, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that a Traditional 510(k) Premarket Notification for ActiPatch® was filed today with the U.S. Food and Drug Administration (FDA). The market clearance...
Source: GlobeNewswire
Date: July, 12 2018 08:30
BioElectronics Corporation's President Andy Whelan Joins Everett Jolly on "Stock Day" to Discuss Progress
PHOENIX, June 13, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire welcomed Andy Whelan, President of BioElectronics Corporation (OTC Pink:BIEL) (“the Company”) back onto the “Stock Day” podcast. Andy spoke with Everett about their progress in the US market, UK market, t...
Source: GlobeNewswire
Date: June, 13 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-120.00060.00070.00070.000537,209,403
2018-12-110.000550.00060.00070.0005112,741,913
2018-12-100.000550.00060.00060.000568,750,060
2018-12-070.00060.00060.00060.000556,566,110
2018-12-060.00070.00060.00070.0005287,906,565

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1220,574,42737,209,40355.2936Short
2018-12-1172,775,376112,741,91364.5504Short
2018-12-1027,654,29268,750,06040.2244Short
2018-12-0727,912,58856,566,11049.3451Short
2018-12-06114,417,485287,806,56539.7550Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BIEL.


About BioElectronics Corp. (OTC: BIEL)

Logo for BioElectronics Corp. (OTC: BIEL)

lt p gt BioElectronics Corporation develops, manufactures, markets and sells consumer medical electronic devices that have both a high efficacy and safety profile for acute and chronic pain. Along with the added benefit of an unmatched cost/benefit ratio, the Company s innovative, miniaturized technology contains an embedded microchip and battery that deliver pulsed electromagnetic field energy, a clinically proven and widely accepted anti inflammatory and pain relief therapy that has only been possible to obtain from large, facility based equipment. BioElectronics markets and sells its current products under the brand names ActiPatch Musculoskeletal Pain Relief, Allay Menstrual Pain Therapy, RecoveryRx Chronic Wounds and Postoperative Recovery, and HealFast Therapy for cats, dogs and horses. The company is headquartered in Frederick, Maryland, USA. BioElectronics is changing the way people heal around the world. Pain has a significant impact on quality of life and with our expanding international presence we are touching the lives of individuals suffering from pain and edema worldwide. Our vision is to provide our highly effective and safe technological solution to pain. We received the Wall Street Journal Technology Innovation Awards with our unique anti inflammatory technology that reduces pain and edema. This technology is the platform for everything that we do. Our current strategic vision is to develop a number of strong brands that build upon our technological platform. Currently, the main applications are aimed at the OTC markets for back pain, knee pain and menstrual pain. We hope to introduce our technology to new markets and additional countries in the near future. lt /p gt

 

 

 

Current Management

  • Andrew A. Whelan / President, CEO
  • Sariah Glosenger /
  • Patricia A Whelan /

Current Share Structure

  • Market Cap: $15,124,782 - 03/20/2018
  • Authorized: 15,000,000,000 - 09/30/2016
  • Issue and Outstanding: 12,603,985,010 - 09/30/2016
  • Float: 7,000,000,000 - 06/04/2015

 


Recent Filings from (OTC: BIEL)

Quarterly Report - UNAUDITED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016
Filing Type: Quarterly Report - UNAUDITED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2Filing Source: OTC Markets
Filing Date: November, 14 2017
Quarterly Report - OTC PINK BASIC DISCLOSURE STATEMENT SEPTEMBER 30, 2017
Filing Type: Quarterly Report - OTC PINK BASIC DISCLOSURE STATEMENT SEPTEMBER 30, 2017Filing Source: OTC Markets
Filing Date: November, 14 2017

 

 


Daily Technical Chart for (OTC: BIEL)

Daily Technical Chart for (OTC: BIEL)


Stay tuned for daily updates and more on (OTC: BIEL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BIEL)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BIEL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BIEL and does not buy, sell, or trade any shares of BIEL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/